NCT07480993Completed
Serum Betatrophin Levels in Normal-Weight and Overweight Adolescents With PCOS
Evaluation of Serum Betatrophin Levels in Normal-Weight and Overweight Adolescents With Polycystic Ovary Syndrome
Source: ClinicalTrials.gov · Last updated 18 Mar 2026
Brief summary (registry, in English)
Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder in adolescents and women of reproductive age and is frequently associated with insulin resistance and an increased risk of metabolic complications. The mechanisms underlying these metabolic abnormalities are not fully understood. Betatrophin (angiopoietin-like protein 8, ANGPTL8) is a liver- and adipose tissue-derived protein involved in lipid and glucose metabolism and has been suggested to be associated with insulin resistance and metabolic stress. This study aims to evaluate serum betatrophin levels in adolescents with PCOS compared with age-matched healthy controls. Adolescents with PCOS will also be categorized according to body mass index (BMI) as normal-weight or overweight to investigate the potential influence of body weight. Additionally, the relationships between betatrophin levels and anthropometric parameters, hormonal profiles, and markers of insulin resistance will be examined.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 90 (actual)
- First submitted
- 14 Mar 2026
- Start date
- 15 Jan 2026
- Primary completion date
- 2 Mar 2026
- Lead sponsor
- Ankara City Hospital Bilkent
- NCT number
- NCT07480993
What you commit to
- Study type: Observational
- Participants enrolled: 90
- From 15 Jan 2026 to the primary completion date, 2 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Cardiovascular diseases including hypertension
- Type 1 or type 2 diabetes mellitus
- Primary adrenal insufficiency
- Thyroid dysfunctions including Hashimoto thyroiditis and Grave's disease
- Renal insufficiency
- Genetic disorders in chromosome constitution or karyotype analysis including monosomy X, trisomy X and gene mutations as BMP15, FMR I, POFIB, and GDF9
- Neurologic diseases
- Psychiatric disorders
- Autoimmune diseases or syndromes including Addison's disease, autoimmune syndromes, scleroderma, Sjogren's syndrome, myasthenia gravis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and familial Mediterranean fever
- History of any malignancy
- History of exposure to chemotherapeutic agents or radiotherapy
Other
- Morbid obesity
- Uterine fibroids
- Hepatic dysfunctions
Who the study is looking for
- Adolescent females aged 16-23 years
- Post-menarche status
- Diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam criteria (for Groups I and II)
- Age-matched healthy females without PCOS for control group (Group III).
- Ability and willingness to provide informed consent/assent
- Willingness to comply with study procedures and blood sample collection
Age in the registry: 16 years to 23 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ankara Bilkent City Hospital Coordinator of this site? Confirm its status | Ankara | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.